ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1563

Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience

David Fiorentino1, Mark Lebwohl2, Vincent Ho3, Richard Langley4, Kavitha Goyal5, Steve Fakharzadeh6, Steve Calabro5 and Wayne Langholff7, 1Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, 2Mount Sinai Medical Center, New York, NY, 3University of British Columbia, Vancouver, BC, Canada, 4Dalhousie University, Halifax, NS, Canada, 5Janssen Services, LLC, Horsham, PA, 6Janssen Services, LLC, Spring House, PA, 7Janssen Research and Development, LLC, Spring House, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Malignancy, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study.

Methods PSOLAR is a multicenter, longitudinal, observational study evaluating long-term safety and clinical outcomes for patients eligible to receive treatment with biologics and/or conventional systemic agents for psoriasis (includes patients with self-reported psoriatic arthritis. The incidence of malignancies excluding NMSC (ie, basal/squamous cell carcinomas) in PSOLAR overall and by treatment groups is reported. Rates of malignancy are assessed using a definition of exposure based on whether patients had ever been exposed to a given therapy at any time prior to the event. In cases of exposure to >1 therapy, the rule for attribution of malignancy to a treatment group is ustekinumab first, infliximab/golimumab second, other biologics third (nearly all adalimumab or etanercept), or non-biologic therapy fourth, which is consistent with the pre-specified analytic plan.

Results PSOLAR is fully enrolled and as of the August 23, 2013 data cut has 31, 818 cumulative patient-years of follow up with 12, 095 patients; 36% of those patients had self-reported psoriatic arthritis.  Unadjusted cumulative rates of malignancy (excluding NMSC) overall and across treatment groups: overall 0.68 events per 100 patient years of observation (PYO) [95% CI: 0.59, 0.77; 215/31818], ustekinumab 0.51 per 100 PYO [95% CI: 0.37, 0.68; 45/8870 PYO], infliximab/golimumab (almost exclusively infliximab) 0.64 per 100 PYO [95% CI: 0.42, 0.93; 27/4205, other biologics (almost exclusively etanercept/adalimumab) 0.74 per 100 PYO [95% CI: 0.60, 0.91; 98/13167], and non-biologic therapy 0.81 per 100 PYO [95% CI: 0.59, 1.08; 45/5576].  The cumulative rates per 100 PY for the overall registry population for the most frequent specific malignancies were: breast cancer 0.13 [40], prostate cancer 0.09 [30], lung cancer 0.08 [26], and melanoma 0.07 [22].  Limitations: Rates have not been adjusted for demographic and clinical differences among treatment groups and are subject to attribution rules.

Conclusion In the current evaluation, reflecting a median duration of 2.5 years of follow-up, cumulative unadjusted rates of malignancies in PSOLAR are comparable across treatment groups. The most frequently reported malignancies in the registry are comparable with the most frequently reported malignancies in the general population.  Additional evaluation of malignancies with accruing longitudinal exposure will be informative.


Disclosure:

D. Fiorentino,

Janssen Scientific Affairs, LLC,

2;

M. Lebwohl,

Janssen Scientific Affairs, LLC,

2;

V. Ho,

Janssen Scientific Affairs, LLC,

2;

R. Langley,

Janssen Scientific Affairs, LLC,

2;

K. Goyal,

Janssen Scientific Affairs, LLC,

3;

S. Fakharzadeh,

Janssen Scientific Affairs, LLC,

3;

S. Calabro,

Janssen Scientific Affairs, LLC,

3;

W. Langholff,

Janssen Scientific Affairs, LLC,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/malignancies-in-the-psoriasis-longitudinal-assessment-and-registry-study-cumulative-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology